XML 76 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
Major Customers and Concentration of Credit Risk
 12 Months Ended
Dec. 31, 2014
Risks and Uncertainties [Abstract]  
Major Customers and Concentration of Credit Risk
Major Customers and Concentration of Credit Risk
 
Customer
2014
 
% of Total
Revenue
 
2013
 
% of Total
Revenue
 
2012
 
% of Total
Revenue
Roche
$
7,357,346

 
70
%
 
$
9,181,759

 
68
%
 
$
—

 
—
%
NIAID
1,229,084

 
12

 
2,090,939

 
16

 
2,831,115

 
69

GeneOne (affiliated entity)
479,464

 
5

 
425,000

 
3

 
577,467

 
14

NIH Research Project Grant
694,457

 
6

 
152,499

 
1

 
—

 
—

All other
696,415

 
7

 
1,617,149

 
12

 
710,070

 
17

Total Revenue
$
10,456,766

 
100
%
 
$
13,467,346

 
100
%
 
$
4,118,652

 
100
%


During the years ended December 31, 2014, 2013 and 2012, the Company recognized revenue from various license fees, collaborative research and development agreements, grants and government contracts. As of December 31, 2014, $2.3 million or 82% and $190,000 or 7% of accounts receivable was attributed to Roche and the NIAID, respectively. As of December 31, 2013, $2.6 million or 79% and $382,000 or 12% of accounts receivable was attributed to Roche and the NIAID, respectively.
There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.